Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.

Journal of psychopharmacology (Oxford, England) - 1 Aug 2016

de Jong Simone, Vidler Lewis R, Mokrab Younes, Collier David A, Breen Gerome

Abstract excerpt

Genome-wide association studies (GWAS) have identified thousands of novel genetic associations for complex genetic disorders, leading to the identification of potential pharmacological targets for novel drug development. In schizophrenia, 108 conservatively defined loci that meet genome-wide significance have been identified and hundreds of additional sub-threshold associations harbour information on the genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Quinolines

Share to Schizophrenia

Source

Identifiers

PMID: 27302942
DOI: 10.1177/0269881116653109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.PMID 27302942Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

Identifying drug targets for schizophrenia through gene prioritization.Semantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Potentially repurposable drugs for schizophrenia identified from its interactomeSemantic proximity Read ↗

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read ↗

Identifying drug targets for schizophrenia through gene prioritizationSemantic proximity Read ↗

Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.Semantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Using genome-wide association results to identify drug repurposing candidatesSemantic proximity Read ↗

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Semantic proximity Read ↗

Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia.Semantic proximity Read ↗

Pathway and network embedding methods for prioritizing psychiatric drugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.